NCT05322850
Phase I/II Trial: Engineered Donor Graft (Orca Q) for Pediatric Hematopoietic Cell Transplant (HCT)
At risk: Primary completion moved at least 11 months later.
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 23 versions: 21 with changes below, 2 re-verified with no change. See every version on ClinicalTrials.gov ↗
Notable Primary completion pushed from Sep 2026 to Sep 2027 Show 4 more changesShow less
- Eligibility criteria expanded, about 50 words
- Study completion pushed from Sep 2027 to Sep 2028
- Secondary endpoints: details revised at 4 of 10 entries
- Site details revised at 3 of 4 sites
- Notable Recruitment resumed after suspension
- Site details revised at 4 of 4 sites
- Collaborators: 2 to 1
- Stopped Trial status: Recruiting to Suspended Sponsor's reason: Seeking additional funding sources
- Site details revised at 4 of 4 sites
- Minor Site contacts updated at 1 of 4 sitesv19
- Minor Site contacts updated at 1 of 4 sitesv17
Show 15 earlier versionsHide 15 earlier versions
- Minor Study sites revised (4)v16
- Minor Site details revised at 1 of 4 sitesv15
- Minor Site details revised at 1 of 4 sitesv14
- Notable Trial status: Suspended to Recruiting
- Study sites revised (4)
- Minor Study sites: 3 to 4v12
- Stopped Trial status: Recruiting to Suspended Sponsor's reason: no manufacturing slots available from sponsor
- Site details revised at 3 of 3 sites
- Minor Start date: Aug 8, 2022 to Aug 16, 2022v10
- Minor Study sites: 2 to 3v9
- Minor Site details revised at 1 of 2 sitesv8
- Notable Trial status: Suspended to Recruiting
- Site details revised at 2 of 2 sites
- Stopped Trial status: Recruiting to Suspended Sponsor's reason: awaiting manufacturing slots from sponsor
- Study sites: 1 to 2
- Minor Site contact updatedv5
- Minor Start date changed from estimate of Sep 2022 to Aug 8, 2022v4
Notable Trial status: Not Yet Recruiting to Recruitingv3 Show 4 more changesShow less
- Eligibility criteria expanded, about 150 words
- Primary endpoints: 1 to 2
- Secondary endpoints: 11 to 10
- Site details revised
- Minor Site contact updatedv2
- Study First Submitted
- Stopped: terminated, suspended or withdrawn
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Primary graft failure
Timeframe: 28 days
Secondary graft failure
Timeframe: 100 days
Secondary (10)
Non-relapse mortality (12 months post-transplant)
Non-relapse mortality (24 months post-transplant)
Overall survival
Relapse rate (12 months post-transplant)
Relapse rate (24 months post-transplant)
Show 5 moreShow less
Rate of acute GVHD
Rate of chronic GVHD
Serious infection rate
Treatment-Emergent Adverse Events
Graft-versus-host disease (GVHD)-free, relapse-free survival
Arms and interventions
Orca-QExperimental
Biologicals: Orca-Q
Sites
4 sites in 1 country